Despite the entry of Velcade to the MM market late last year, Thalomid sales are sitting at 96% to budget YTD. While patient starts have dropped compared to last year the monthly average seems to have stabilised at roughly 50 - 60 new starts a month.
The good news is that analysis shows there continues to be room for growth in the MM market space.
The MM portfolio is showing Revlimid sales hitting 111% to budget YTD as a result of strong growth against PYTD sales for all territories.
Sales Update
By Mystique
With six months down, 2013 is shaping up to be another
year of stellar performances.
The sales team continue to beat target new Revlimid starts nationally and a concerted effort to increase duration of therapy has resulted in an ever expanding active patient bubble.